Protagonist Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow25.39
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for PTGX is 25.39. That is above the Healthcare sector average of 22.57. Investors often review this figure alongside Protagonist Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, PTGX currently prints 25.39 for P/E ratio, while the sector average sits near 22.57. That is roughly 12.5% above the sector mean. Large gaps often invite a closer look at Protagonist Therapeutics's growth, margins, and balance sheet.
A P/E ratio of 25.39 for Protagonist Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (22.57) and with PTGX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting PTGX's P/E ratio (25.39), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Protagonist Therapeutics's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
